Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan-Mar;60(1):10-16.
doi: 10.4103/psychiatry.IndianJPsychiatry_104_18.

A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia

Anmol Singh  1 , Ram Pratap Beniwal  1 , Prachi Kukshal  2 , Triptish Bhatia  1 , B K Thelma  2 , Smita N Deshpande  1
Affiliations

A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia

Anmol Singh et al. Indian J Psychiatry. 2018 Jan-Mar.

Abstract

Background: Treatment response can be predicted in schizophrenia by DNA information in the drug metabolism pathways. This study aimed to examine clinical characteristics and genetic determinant (s) of early response to olanzapine treatment in schizophrenia using specified drug metabolizing genes.

Materials and methods: Consenting participants (n = 33) suffering from schizophrenia were diagnosed on Diagnostic Interview for Genetic Studies. Oral olanzapine was administered in an incremental dose up to 10 mg (2 weeks) and 20 mg (6 weeks). All participants were tested on Positive and Negative Syndrome Scale, Clinical Global Impressions, and Global Assessment of Functioning at 0, 2, and 6 weeks. Side effects were also evaluated. After 2 weeks, 11 (33.33%) fulfilled criteria for early response, whereas 17 (51.52%) responded at 6 weeks. We investigated the contribution of clinical factors and five polymorphisms (rs2740574, rs2470890, rs762551, rs3892097, and rs1065852) in predicting response to olanzapine at 2 and 6 weeks of treatment with a standard dose.

Results: Severity of positive symptoms at baseline was associated with response at 2 weeks (P = 0.01) while higher scores on Scale for the Assessment of Negative Symptoms (SANS) at baseline was associated with response at both 2 (P = 0.04) and 6 weeks (P = 0.03). None of the five single nucleotide polymorphisms (SNPs) selected were significantly associated with response to olanzapine.

Conclusions: Olanzapine is an effective and safe drug. Positive and Negative Syndrome Scale positive score and SANS score were variably associated with response at 2 and/or 6 weeks. Replicate studies with bigger sample size are warranted for conclusive results in the Indian population for genetic association.

Keywords: Drug metabolizing genes; genotypes; olanzapine; responders; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: The quest for individualized therapy. Hum Mol Genet. 2002;11:2517–30. - PubMed
    1. Malhotra AK, Murphy GM, Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780–96. - PubMed
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23. - PubMed
    1. Nnadi CU, Goldberg JF, Malhotra AK. Genetics and psychopharmacology: Prospects for individualized treatment. Essent Psychopharmacol. 2005;6:193–208. - PMC - PubMed
    1. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, et al. Body weight gain induced by atypical antipsychotics: An extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35:207–11. - PubMed